The survey was adapted in recent years to capture data on other newly introduced disease indications for CAR-T cell treatment, such as myeloma which increased from 470 in 2022 to 736 in 2023 and other grouped indications (e.g., AID and solid tumors) where 124 were reported in 2023 (36 of which were for AID) [22–34]. The gene discussed is AICDA; the disease is plasma cell myeloma.